苯乙双胍增强ERK抑制剂在NF1突变黑色素瘤中的疗效
NF1突变黑色素瘤缺乏靶向治疗,临床前研究评估ERK抑制剂SCH772984与双胍类苯乙双胍联合。两药在细胞活力检测中显示强协同并协同诱导凋亡,且需联合才能完全抑制mTOR信号。SCH772984增加耗氧率并扩增KDM5B阳性耐药亚群,苯乙双胍抑制该亚群并减少耐药克隆出现。
要点
- ERK抑制剂单药疗效有限,联合苯乙双胍在NF1突变黑色素瘤中显示协同作用。
- 联合用药可完全抑制mTOR信号并协同诱导凋亡。
- 苯乙双胍抑制SCH772984诱导的KDM5B阳性耐药亚群,减少耐药克隆产生。
核心结论
- ERK抑制剂SCH772984与苯乙双胍联合在NF1突变黑色素瘤细胞中显示协同作用,值得临床研究。
研究设计与样本
- 临床前研究,使用NF1突变黑色素瘤细胞系进行细胞活力检测、凋亡分析、信号通路检测及长期培养。
主要发现
- SCH772984与苯乙双胍联合在细胞活力检测中显示强协同并协同诱导凋亡。
- 两药联合才能完全抑制mTOR信号。
- SCH772984增加耗氧率和PGC1-α表达,苯乙双胍降低耗氧率。
- SCH772984扩增KDM5B阳性慢周期耐药亚群,苯乙双胍抑制该亚群并减少耐药克隆出现。
临床怎么用
- 对于NF1突变黑色素瘤,可考虑ERK抑制剂联合苯乙双胍的临床研究。
局限性
- 研究为临床前细胞实验,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inactivation of the tumor suppressor neurofibromin 1 (NF1) presents a newly characterized melanoma subtype, for which currently no targeted therapies are clinically available. Preclinical studies suggest that extracellular signal-regulated kinase (ERK) inhibitors are likely to provide benefit, albeit with limited efficacy as a single agent; therefore, there is a need for rationally designed combination therapies. Here, we evaluate the combination of the ERK inhibitor SCH772984 and the biguanide phenformin. A combination of both compounds showed potent synergy in cell viability assays and cooperatively induced apoptosis. Treatment with both drugs was required to fully suppress mechanistic target of rapamycin signaling, a known effector of NF1 loss. Mechanistically, SCH772984 increased the oxygen consumption rate, indicating that these cells relied more on oxidative phosphorylation upon treatment. Consistently, SCH772984 increased expression of the mitochondrial transcriptional coactivator peroxisome proliferator-activated receptor gamma, coactivator 1-α. In contrast, cotreatment with phenformin, an inhibitor of complex I of the respiratory chain, decreased the oxygen consumption rate. SCH772984 also promoted the expansion of the H3K4 demethylase KDM5B (also known as JARID1B)-positive subpopulation of melanoma cells, which are slow-cycling and treatment-resistant. Importantly, phenformin suppressed this KDM5B-positive population, which reduced the emergence of SCH772984-resistant clones in long-term cultures. Our results warrant the clinical investigation of this combination therapy in patients with NF1 mutant melanoma.
引用
- Trousil S, Chen S, Mu C, et al. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. J Invest Dermatol. 2017. PMID: 28143781. doi:10.1016/j.jid.2017.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。